Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to 79 MUSD, of which 26 MUSD were sales in the USA.
The royalty for the third quarter amounted to 57 MSEK (6.1 MEUR). Medivir’s royalties based on sales for the third quarter are calculated from the third royalty tier. In addition Medivir has received an adjustment of 11 MSEK (1.2 MEUR) related past royalty payments. The total royalty income reported for the third quarter will therefore amount to 70 MSEK (7.3 MEUR).
| OLYSIO® global net sales | Sales in MUSD | ||
| Market | Q3 -2015 | Q3-2014 | Change |
| US | 26 | 671 | -96% |
| RoW | 53 | 125 | -56% |
| Total global net sales MUSD | 79 | 796 | -90% |
Medivir will publish its third quarter report on November 20, 2015 at 8.30 CET followed by a conference call for investors, analysts and the media at 14.00 CET. More information about the conference call/webcast will be posted at www.medivir.com.
For more information please contact:
Ola Burmark, CFO, Medivir AB, mobile: +46 725 480 580
Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 13.30 CET on 13 October 2015.
About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.